Subconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium

Objective: to determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium. Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2ml/ 2.5mg). vascularity and thickness of Pterygium was graded. size of the pterygium (measured by surface area in cm2) was recorded from baseline to 6 months after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in grading, size, vascularity, thickness and color intensity. Results: 9 males (45%) , 11 females (55%) of 20 patients were conducted in study with a mean age of 50.46 years±18.30 (rang 38-70). There was a significant reduction in grading with significant difference in the mean surface area of pterygium at different intervals ( 0.05) and the size of pterygium was reduced. The reduction of color intensity was significant (P =0.031). No significant topical or systemic adverse reactions were recorded Conclusions: Subconjunctival bevacizumab injection is useful in management of patients with recurrent pterygium without significant local or systemic adverse effects.